Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

MRKR

+ Watchlist+ Portfolio

Marker Therapeutics, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.84
52-Week Range
$0.81 – $2.46
Market Cap
$14.23M
P/E (TTM)
—
EPS (TTM)
-0.39
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.85
PEG Ratio
—
Return on Equity
-59.21%
Return on Assets
-38.69%
Gross Margin
7.47%
Operating Margin
-457.96%
Profit Margin
0.00%
Current Ratio
6.26
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-7.18M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$5.19M

Market Snapshot

About

Clinical-stage immuno-oncology company developing T cell-based therapies to treat hematologic malignancies and solid tumors. Lead programs utilize multi-targeted autologous tumor infiltrating lymphocytes (TIL) designed to recognize and kill cancer cells with multiple antigens. Focus on accessible off-the-shelf solutions.